Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Proposal, Medicare Modernization Allocated $153 Bil. Under Bush Plan

Executive Summary

President Bush's drug coverage initiative and Medicare modernization would be allocated $11 bil. from the budget surplus in FY 2002 under the Administration's budget plan sent to Congress Feb. 28.

You may also be interested in...



Bush "Helping Hand" Rx Plan Is Gaining Support Of States, Thompson Says

President Bush's interim state-based drug plan "Immediate Helping Hand" is picking up support from some states, HHS Secretary Thompson indicated.

Bush "Helping Hand" Rx Plan Is Gaining Support Of States, Thompson Says

President Bush's interim state-based drug plan "Immediate Helping Hand" is picking up support from some states, HHS Secretary Thompson indicated.

Amgen Working With Sen. Kennedy On Medicare Rx Benefit Bill

Amgen is working with the ranking Democrat on the Senate Health Committee, Sen. Kennedy (D-Mass.), to develop a Medicare prescription drug benefit bill.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel